United General Ltd Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: London United Kingdom (2018)
Status: No NME R&D (2018)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
None

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (2)

Key: United General Ltd (0) Acquired (2)

aldesleukin (Proleukin) (4 trials)

histamine (4 trials)

Drugs in Phase 2 Trials (5)

Key: United General Ltd (0) Acquired (5)

amitriptyline (elavil) (2 trials)

azacitidine (vidaza) (1 trial)

Bertilimumab (2 trials)

gabapentin (neurontin) (1 trial)

ketamine (ketalar) (2 trials)

Drugs in Phase 1 Trials (1)

Key: United General Ltd (0) Acquired (1)

crinobulin (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 9
  • # of Trial APIs: 8